Effect of sulphasalazine and sulphapyridine on neutrophil superoxide production: role of cytosolic free calcium

Lars Kanerud, Ingjald Hafström, Bo Ringertz

Abstract

As the neutrophil granulocyte plays an important part in rheumatoid inflammation the effect of sulphasalazine on neutrophil function was studied. The results show that sulphasalazine, and its metabolite sulphapyridine, inhibit neutrophil superoxide production elicited by the receptor mediated stimulus *N*-formyl-methionyl-leucyl-phenylalanine (fMLP) and by the calcium ionophore A23187. This effect seems to be dependent on inhibition of intracellular Ca^{++} increase as both substances reduce this increase upon cell activation with fMLP and A23187. Sulphasalazine and sulphapyridine do not inhibit superoxide production after stimulation with the ester phorbol myristate acetate, a stimulus response coupling which is independent of intracellular Ca^{++} increase. The reported inhibition of superoxide generation may explain, at least partly, the antirheumatic property of sulphasalazine.

Sulphasalazine is now widely accepted as a disease modifying drug in the treatment of rheumatoid arthritis.¹⁻⁵ The mechanisms by which sulphasalazine exerts its antirheumatic properties are largely unknown, however, and it is also unclear which part of the molecule is active.

Less than 30% of ingested sulphasalazine is absorbed in the small intestine.⁶⁻⁷ The remaining drug is cleaved by colonic bacteria into sulphapyridine and 5-aminosalicylic acid.⁶⁻⁸⁻⁹ Sulphapyridine is almost totally absorbed whereas 5-aminosalicylic acid largely is retained in the colon and can only be detected in serum in very small amounts.⁷⁻¹⁰ In the colon 5-aminosalicylic acid is present in high concentrations and has been considered to be the therapeutic moiety of sulphasalazine in ulcerative colitis.¹¹⁻¹²

In rheumatoid arthritis, on the other hand, it has during the last years been proposed that sulphapyridine or sulphasalazine, or both, are responsible for the antirheumatic activity.¹³⁻¹⁴ Suggested explanations for this activity include antibacterial effect in the colon¹⁵ or immunosuppressive activity.¹⁶⁻¹⁹ Sulphasalazine also interferes with prostaglandin metabolism.²⁰⁻²¹ A further proposal is that sulphasalazine or sulphapyridine affects neutrophil function.

Neutrophils play an important part in the pathogenesis of the inflammatory process in rheumatoid arthritis. Thus upon activation these cells release lysosomal enzymes and reactive oxygen radicals,²²⁻²⁴ which can provoke tissue destruction and mediate abnormal immune

reactions.²⁵⁻²⁶ It has been shown that neutrophil superoxide production as well as chemotaxis elicited by the synthetic tripeptide *N*-formyl-methionyl-leucyl-phenylalanine (fMLP) were reduced by sulphasalazine,²⁷⁻²⁸ and that this reduction might depend on sulphasalazine inhibiting the binding of fMLP to its receptors on neutrophils.²⁷ Furthermore, sulphasalazine or sulphapyridine decreased superoxide production and lysosomal enzyme release in response to serum coated zymosan and immune complexes.²⁸⁻³⁰ Whether these last effects were due to inhibition of particle binding has not been studied. Consequently, it is unclear if sulphasalazine affects neutrophil functions merely by inhibiting binding of fMLP and particles to its receptors or if sulphasalazine also affects intrinsic neutrophil properties. It was thus of interest to investigate further the way in which sulphasalazine and sulphapyridine affect neutrophil function. For that purpose neutrophil superoxide production was stimulated, by, in addition to fMLP, the calcium ionophore A23187 and the tumour promoting ester phorbol myristate acetate (PMA), agents with different triggering mechanisms for stimulation of neutrophil NADPH-oxidase.³¹⁻³² The results are discussed in relation to the initiating mechanisms of the respiratory burst, especially with reference to the noted effects of sulphasalazine and sulphapyridine on intracellular Ca^{++} mobilisation.

Materials and methods

NEUTROPHIL ISOLATION

Peripheral blood neutrophils from normal human subjects were isolated by Percoll discontinuous gradient centrifugation³³ and resuspended in Hanks's balanced salt solution (HBSS) without albumin. This procedure yielded preparations containing >95% of neutrophils.

NEUTROPHIL FUNCTION ASSAYS

Where indicated, neutrophils were preincubated with sulphasalazine or sulphapyridine dissolved in HBSS, at concentrations of 1 $\mu\text{mol/l}$ to 1 mmol/l for 10 minutes at 37°C. At these concentrations sulphasalazine and sulphapyridine did not affect cell viability measured by trypan blue exclusion. As Nielsen *et al* have shown that the inhibitory effect of sulphasalazine on neutrophil function occurs rapidly and is almost maximal after 10 minutes' incubation,³⁴ this incubation time was chosen.

Superoxide generation

Superoxide production by neutrophils was

Section of Rheumatology,
Department of
Medicine III,
Karolinska Institute,
Södersjukhuset,
100 64 Stockholm,
Sweden

L Kanerud
I Hafström
B Ringertz

Correspondence to:
Dr Kanerud

Accepted for publication
15 June 1989

determined spectrophotometrically by monitoring superoxide dismutase inhibitable reduction of cytochrome *c* as described previously.³⁵ Briefly, to neutrophils (2.5×10^6 cells/ml) in 2 ml HBSS was added 50 μ M ferricytochrome *c* before stimulation with 0.1 μ M fMLP, 5 μ M A23187, or 10 μ M PMA, and the change in absorbance at 550 nm was measured continuously at 37°C in a Perkin-Elmer Lambda 7 spectrophotometer. Sulphasalazine or sulphapyridine was present during stimulation or cells were first incubated with sulphasalazine/sulphapyridine and then washed before addition of cytochrome *c* and stimulus. Reduction of cytochrome *c* stimulated by fMLP and A23187 was measured at the end point of the reactions. The results for PMA were calculated as the linear rate of cytochrome *c* reduction measured between 3 and 5.5 minutes after stimulation. As the sensitivity of neutrophils to stimulation varies from donor to donor the effect of sulphasalazine and sulphapyridine is expressed as the percentage of superoxide produced by control neutrophils incubated without sulphasalazine or sulphapyridine.

Cytosolic free Ca^{++} concentration

To measure cytosolic free Ca^{++} concentration the fluorescent probe fura-2 was used because of its brighter fluorescence and improved selectivity to Ca^{++} over other divalent cations, compared with—for example, Quin-2.³⁶ Neutrophils (5×10^6 cells/ml) in HBSS supplemented with 20 mM *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulphonic acid (HEPES) pH 7.4 were loaded with 0.5 μ M fura-2AM (fura-2-tetra-acetomethoxy ester) for 30 minutes at 37°C. The cells were then washed twice and resuspended in HBSS with HEPES in a concentration of 2.5×10^6 cells/ml before incubation with sulphasalazine/sulphapyridine or buffer for 10 minutes. Subsequently, fMLP 0.1 μ M or ionomycin 2 μ M was added as stimulus. Ionomycin was used instead of A23187 as the intrinsic fluorescence of the latter interferes with the emission spectra of the fura-2 complex. Fluorescence measurements were performed in a Hitachi model F-3000 spectrofluorometer with quartz cuvettes at a constant temperature of 37°C and with continuous stirring of cells. Excitation and emission wavelengths were 340 and 510 nm respectively. The system was controlled by addition of EGTA, TRIS buffer, Triton X-100, and $CaCl_2$.³⁷ The calculated concentration of cytosolic free Ca^{++} was: $[Ca^{++}] = kd(F - F_{min}) / (F_{max} - F)$, where *F* is the measured fluorescence, *F*_{min} the fluorescence after lysing the cells with Triton X-100, and *F*_{max} the fluorescence from calcium saturated dye. The *kd* value is 224 nmol/l.³⁶

Results

SUPEROXIDE PRODUCTION

To study possible inhibitory effects of sulphasalazine and sulphapyridine the experiments were performed with optimal concentrations of the stimuli (fMLP 0.1 μ M/l, A23187 5 μ M/l, and PMA 10 μ M/l), thereby achieving maximal

response of neutrophil superoxide generation. Reduction of cytochrome *c* stimulated by fMLP started immediately after addition of stimulus and ended within four to five minutes. Superoxide production elicited by A23187 also started immediately after addition of stimulus but the reaction lasted longer than for fMLP and often did not end until after 10 minutes. Superoxide production stimulated by PMA started after a lag period of approximately 1.5 minutes and the response was protracted.

When neutrophils were incubated with sulphasalazine, 10 μ M/l–0.5 mmol/l, there was a significant reduction of superoxide production stimulated by fMLP and A23187. Sulphasalazine did not inhibit superoxide production when PMA was used as stimulus, however (fig 1).

Similarly, sulphapyridine inhibited fMLP and A23187 elicited superoxide production, but had no effect on PMA induced superoxide production (fig 2).

When neutrophils incubated with sulphasalazine for 10 minutes were washed free from sulphasalazine before stimulation with fMLP and A23187 inhibition of superoxide production was no longer observed. The inhibition by sulphapyridine was, however, partially irrever-

Figure 1: Effects of various concentrations of sulphasalazine on neutrophil superoxide production elicited by fMLP 0.1 μ M/l, ionophore A23187 5 μ M/l, and PMA 10 μ M/l. Neutrophils were incubated with sulphasalazine 1 μ M/l to 0.5 mmol/l before being tested. Results are means and SEM of three to five experiments (different donors) and expressed as a percentage of control cells not exposed to any drug. fMLP = *N*-formyl-methionyl-leucyl-phenylalanine; PMA = phorbol myristate acetate.

Figure 2: Effects of various concentrations of sulphapyridine on neutrophil superoxide production elicited by fMLP 0.1 μ M/l, ionophore A23187 5 μ M/l, and PMA 10 μ M/l. Neutrophils were incubated with sulphapyridine 1 μ M/l to 0.5 mmol/l before being tested. Results are means and SEM of three to five experiments (different donors) and expressed as a percentage of control cells not exposed to any drug. fMLP = *N*-formyl-methionyl-leucyl-phenylalanine; PMA = phorbol myristate acetate.

sible. Thus cells incubated with 0.5 mM sulphapyridine after washing generated 64.1 (SEM 7.2)% superoxide upon fMLP stimulation and upon A23187 stimulation 58.1 (10.2)% superoxide compared with control cells.

Sulphasalazine and sulphapyridine had no effect on basal cytochrome *c* reduction. In addition, neither inhibited superoxide production by a cell free generating system of xanthine plus xanthine oxidase (data not shown). Therefore sulphasalazine and sulphapyridine did not exert their inhibitory effects on oxidative metabolism by scavenging superoxide anion directly.

INCREASE OF CYTOSOLIC Ca^{++} CONCENTRATION

As superoxide production elicited by both fMLP and ionophore was inhibited by sulphasalazine and sulphapyridine we next studied a common signal transduction event essential for ligand and calcium ionophore but not for PMA elicited neutrophil function. Consequently, we measured the effect of sulphasalazine or sulphapyridine on the ability of fMLP and of a calcium ionophore, ionomycin, to induce changes in neutrophil free Ca^{++} . We used neutrophils loaded with fura-2, a dye that forms a fluorescent complex with Ca^{++} . An increase in fluorescence upon stimulation of cells is considered to correlate with an increase of cytosolic free Ca^{++} . Both fMLP 0.1 $\mu\text{mol/l}$ and ionomycin 2 $\mu\text{mol/l}$ rapidly increased the fluorescence and, thus, the cytosolic Ca^{++} concentration. Neutrophils at rest had a cytosolic Ca^{++} concentration of 70 (SEM 9) nmol/l, which upon cell activation with fMLP increased to 401 (15) nmol/l and upon activation with ionomycin to 422 (38) nmol/l. The intention was to see if sulphasalazine 100 $\mu\text{mol/l}$ and sulphapyridine 100 $\mu\text{mol/l}$, which significantly inhibited superoxide production, inhibited this Ca^{++} increase. Sulphasalazine 100 $\mu\text{mol/l}$ had a slightly yellow colour, however, which interfered with the light emission. We instead used sulphasalazine 10 $\mu\text{mol/l}$ as it was not feasible to wash sulphasalazine

Figure 3: Effects of sulphasalazine and sulphapyridine on neutrophil intracellular Ca^{++} increase elicited by fMLP 0.1 $\mu\text{mol/l}$ or ionomycin 2 $\mu\text{mol/l}$. Neutrophils were either incubated with sulphasalazine 10 $\mu\text{mol/l}$ before stimulation or incubated with sulphapyridine 100 $\mu\text{mol/l}$ and then washed before addition of stimulus. Results are means and SEM of four experiments and expressed as a percentage of control cells not exposed to any drug but otherwise similarly treated. fMLP = N-formyl-methionyl-leucyl-phenylalanine.

away because of the shown reversible effect (see above). Sulphapyridine 100 $\mu\text{mol/l}$ also interfered with the fluorescence, but as the effect on superoxide production was only partially reversible the cells were washed after incubation with sulphapyridine 100 $\mu\text{mol/l}$ and thereafter stimulated with fMLP and ionophore.

The results showed that sulphasalazine 10 $\mu\text{mol/l}$ significantly inhibited both fMLP and ionomycin induced increase of cytosolic free Ca^{++} . Sulphapyridine 100 $\mu\text{mol/l}$ also inhibited both responses when cells were washed after incubation and before stimulation (fig 3).

Discussion

In this study we have shown that sulphasalazine and sulphapyridine inhibit superoxide production elicited by the tripeptide fMLP and the calcium ionophore A23187 in a dose dependent manner, and that they also inhibit mobilisation of cytosolic free Ca^{++} induced by the same stimuli. Sulphasalazine and sulphapyridine do not, however, affect PMA elicited superoxide generation, a stimulus response coupling that is independent of increase of cytosolic free Ca^{++} .^{38 39}

Neutrophils can be triggered to generate superoxide anions by a variety of stimuli, including the tripeptide fMLP, calcium ionophores, and the tumour promoter PMA. The signal transduction pathways by which these stimuli activate the membrane oxidase are different, however (fig 4).

The inhibition of fMLP elicited superoxide generation by sulphasalazine and sulphapyridine

Figure 4: Schematic illustration of neutrophil activation: fMLP binds to a specific surface membrane receptor, which by guanine nucleotide binding stimulates phospholipase C dependent phosphoinositide hydrolysis to generate inositol 1,4,5-triphosphate and diacylglycerol. Inositol 1,4,5-triphosphate causes release of Ca^{++} from intracellular stores, whereas diacylglycerol activates protein kinase C, which are both suggested to be second messengers for eliciting functional responses—that is, activating the oxidase enzyme. Phorbol myristate acetate binds to cytosolic receptors, which are equivalent to protein kinase C, the occupancy of which activates the membrane oxidase, thereby eliciting superoxide production. fMLP = N-formyl-methionyl-leucyl-phenylalanine; LTB₄ = leukotriene B₄; PIP₂ = phosphoinositide diphosphate; DAG = diacylglycerol; PMA = phorbol myristate acetate; IP₃ = inositol 1,4,5-triphosphate.

shown here might theoretically be located at any step in the stimulus response coupling. One possibility is that the drugs inhibit binding of fMLP to its receptor, which has been reported earlier for sulphasalazine.²⁷ The inhibition of superoxide generation may, however, not solely be attributed to inhibition of fMLP binding. Other mechanisms are probable because sulphasalazine and sulphapyridine also reduced superoxide release by A23187. The similar dose-response curves for the effect of sulphasalazine and sulphapyridine on superoxide generation elicited by fMLP and A23187 suggest there may be a common block.

Calcium ionophores increase cytosolic free Ca^{++} directly by transporting calcium into the cell, thus bypassing the initial steps for fMLP activation. The findings reported here that sulphasalazine and sulphapyridine inhibit increase of cytosolic Ca^{++} induced by both fMLP and the calcium ionophore ionomycin indicate that they interfere with calcium mobilisation. According to earlier work, such a block of calcium redistribution may well explain the reduced oxidase activation.^{40 41}

Further support for the theory that sulphasalazine and sulphapyridine act by interfering with calcium mobilisation is that neither substance affected superoxide generation induced by PMA. Neutrophil functions stimulated by PMA are not associated with and not dependent on a rise in the level of intracellular free Ca^{++} .^{38 39}

The fact that superoxide generation induced by PMA was unaffected by sulphasalazine and sulphapyridine indicates that these drugs do not impair the oxidase enzyme activity or reduce the amount of enzyme available. It also suggests that sulphasalazine and sulphapyridine do not have a direct oxy radical scavenging action. The other moiety of sulphasalazine, 5-aminosalicylic acid, is however, a known potent scavenger of free radicals,⁴² which implies that the effect of 5-aminosalicylic acid on neutrophil oxidative metabolism cannot be analysed by this superoxide production assay.

A recent hypothesis is that sulphasalazine and sulphapyridine act as inhibitors of neutrophil lipoygenase enzyme. When neutrophils are activated by fMLP and A23187, arachidonic acid is metabolised mainly by 5-lipoygenase to 5-hydroxyeicosatetraenoic acid and leukotriene B_4 .^{43 44} It has been suggested that leukotriene B_4 , which is an activator of neutrophils, is also an intracellular second messenger.⁴⁵ A number of reports suggest that superoxide generation by receptor stimuli and A23187 is linked to arachidonic acid metabolism.⁴⁶⁻⁴⁸ On the other hand, PMA activation of the oxidase enzyme is independent, not only of intracellular calcium increase but also of arachidonic acid metabolism,⁴⁹ and PMA can induce release of neither leukotriene B_4 nor other lipoygenase products.⁵⁰ An inhibitory effect on lipoygenase enzyme might thus explain the demonstrated reductions by sulphasalazine and sulphapyridine on superoxide generation elicited by fMLP and A23187 but probably not the effect on calcium mobilisation. It might further explain the lack of effect on PMA elicited superoxide generation.

The effect of sulphasalazine and sulphapyridine on arachidonic acid metabolism has been investigated previously by a soybean lipoygenase assay,^{51 52} which indicated that sulphasalazine, but not sulphapyridine, inhibits the lipoygenase enzyme. In a study with human neutrophils sulphasalazine, and to a lesser extent sulphapyridine, inhibited leukotriene B_4 and 5-hydroxyeicosatetraenoic acid biosynthesis when cells were exposed to extracellular arachidonic acid and stimulated by A23187.⁵³ Also, when arachidonic acid was incorporated into neutrophils before stimulation with A23187, sulphasalazine inhibited production of the two main 5-lipoygenase products of arachidonic acid, leukotriene B_4 and 5-hydroxyeicosatetraenoic acid.³⁴ The last two reports^{34 53} are difficult to interpret, as the reduced synthesis of lipoygenase products was noted after stimulation with the calcium ionophore A23187. Our finding that sulphasalazine and sulphapyridine inhibit the very first step in calcium ionophore activation, the increase of cytosolic free Ca^{++} , makes it likely that the following steps in the activation pathway also—that is, lipoygenase activation, are inhibited. The reduced synthesis of lipoygenase products might thus follow inhibition of calcium mobilisation, and need not indicate a direct inhibitory effect on the enzyme activity. The pure biochemical assays, however, indicate that sulphasalazine, but not sulphapyridine, inhibits lipoygenase activity.^{51 52}

It can thus be stated that sulphasalazine and sulphapyridine inhibit neutrophil superoxide generation induced by fMLP and A23187, an effect that probably depends mainly on inhibition of calcium mobilisation. Earlier reported inhibition of lipoygenase activity may, however, contribute to the reduced neutrophil activity. Current knowledge indicates that superoxide radicals are associated with the pathogenesis of rheumatoid arthritis. The reported inhibition of superoxide generation by sulphasalazine and sulphapyridine may be one mechanism by which these substances reduce the inflammatory reaction in that disease.

We thank Mrs Ingegärd Friberg and Mrs Pia Spångberg for excellent technical assistance and Mrs Åsa Sagner for skilful secretarial work. Sulphasalazine and sulphapyridine were a kind gift from Pharmacia, Sweden.

- McConkey B, Amos R S, Butler E P, Crockson R A, Crockson A P, Walsh L. Salazopyrin in rheumatoid arthritis. *Agents Actions* 1978; 8: 438-41.
- McConkey B, Amos R S, Durham S, Forster P J G, Hubbal S, Walsh L. Sulphasalazine in rheumatoid arthritis. *Br Med J* 1980; 280: 442-4.
- Neumann V C, Grindulis K A, Hubball S, McConkey B, Wright V. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds Birmingham-trial. *Br Med J* 1983; 287: 1099-102.
- Pullar T, Hunter J A, Capell H A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. *Br Med J* 1983; 287: 1102-4.
- Pinals R S, Kaplan S B, Lawson J G, Hepburn B. Sulfasalazine in rheumatoid arthritis. A double blind, placebo-controlled trial. *Arthritis Rheum* 1986; 29: 427-34.
- Schröder H, Campbell D E S. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. *Clin Pharmacol Ther* 1972; 13: 539-51.
- Azad Khan A K, Truelove S C, Aronson J K. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. *Br J Clin Pharmacol* 1982; 13: 523-8.
- Peppercorn M A, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. *J Pharmacol Exp Ther* 1972; 181: 555-62.
- Das K M, Eastwood M A, McManus J P A, Sircus W. The role of the colon in the metabolism of salicylazosulphapyridine. *Scand J Gastroenterol* 1974; 9: 137-41.

- 10 Peppercorn M A, Goldman P. Distribution studies of salicylazosulphapyridine and its metabolites. *Gastroenterology* 1973; **64**: 240-5.
- 11 Azad Khan A K, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine. *Lancet* 1977; **ii**: 892-5.
- 12 Van Hees P A M, Bakker J H, Van Tongeren J H M. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. *Gut* 1980; **21**: 632-5.
- 13 Pullar T, Hunter J A, Capell H A. Which component of sulphasalazine is active in rheumatoid arthritis? *Br Med J* 1985; **290**: 1535-8.
- 14 Neumann V C, Taggart A J, Le Gallez P, Astbury C, Hill J, Bird H A. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. *J Rheumatol* 1986; **13**: 285-7.
- 15 Neuman V C, Shinebaum R, Cooke E M, Wright V. Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine. *Br J Rheumatol* 1987; **26**: 334-7.
- 16 Holm G, Perlmann P. The effect of antimetabolites on the cytotoxicity by human lymphocytes. In: Dausset J, et al, eds. *Advances in transplantation*. Copenhagen: Munksgaard, 1968: 155-61.
- 17 Sheldon P J, Webb C, Grindulis K A. Sulphasalazine in rheumatoid arthritis: pointers to a gut-mediated immune effect. *Br J Rheumatol* 1987; **26**: 318-9.
- 18 Symmons D P M, Salmon M, Farr M, Bacon P A. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. *J Rheumatol* 1988; **15**: 575-9.
- 19 Comer S S, Jasin H E. In vitro immunomodulatory effects of sulfasalazine and its metabolites. *J Rheumatol* 1988; **15**: 580-6.
- 20 Smith P R, Dawson D J, Swan C H J. Prostaglandin synthetase activity in acute ulcerative colitis: effects of treatment with sulphasalazine, codeine phosphate and prednisolone. *Gut* 1979; **20**: 802-5.
- 21 Hoult J R S, Moore P K. Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle. *Br J Pharmacol* 1980; **68**: 719-30.
- 22 Weissmann G, Zurier R B, Spieler P J, Goldstein I M. Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. *J Exp Med* 1971; **134**: 149s-65s.
- 23 Goldstein I M, Roos D, Kaplan H B, Weissmann G. Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis. *J Clin Invest* 1975; **56**: 1155-63.
- 24 Lehmeyer J E, Snyderman R, Johnston Jr R B. Stimulation of neutrophil oxidative metabolism by chemotactic peptides: influence of calcium ion concentration and cytochalasin B and comparison with stimulation by phorbol myristate acetate. *Blood* 1979; **54**: 35-45.
- 25 McCord J M, Fridovich I. The biology and pathology of oxygen radicals. *Ann Intern Med* 1978; **89**: 122-7.
- 26 Halliwell B. Hypothesis: production of superoxide, hydrogen peroxide and hydroxyl radicals by phagocytic cells: A cause of chronic inflammatory disease? *Cell Biol Int Rep* 1982; **6**: 529-42.
- 27 Stenson W F, Mehta J, Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (fMLP) to its receptor on human neutrophils. *Biochem Pharmacol* 1984; **33**: 407-12.
- 28 Neal T M, Winterbourn C C, Vissers M C M. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. *Biochem Pharmacol* 1987; **36**: 2765-8.
- 29 Molin L, Stendahl O. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis. *Acta Med Scand* 1979; **206**: 451-7.
- 30 Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. *Gut* 1987; **28**: 190-5.
- 31 Babior B M. The respiratory burst of phagocytes. *J Clin Invest* 1984; **73**: 599-601.
- 32 Hurst N P. Molecular basis of activation and regulation of the phagocyte respiratory burst. *Ann Rheum Dis* 1987; **46**: 265-72.
- 33 Ringertz B, Palmblad J, Rådmark O, Malmsten C. Leukotriene-induced neutrophil aggregation in vitro. *FEBS Lett* 1982; **147**: 1-3.
- 34 Nielsen O H, Bukhave K, Elmgreen J, Ahnfelt-Rønne I. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. *Dig Dis Sci* 1987; **32**: 577-82.
- 35 Seligmann B E, Fletcher M P, Gallin J I. Histamine modulation of human neutrophil oxidative metabolism, locomotion, degranulation, and membrane potential changes. *J Immunol* 1983; **130**: 1902-9.
- 36 Grynkiewicz G, Poenie M, Tsien R Y. A new generation of Ca^{2+} indicators with greatly improved fluorescence properties. *J Biol Chem* 1985; **260**: 3440-50.
- 37 Metcalf J A, Gallin J I, Nauseef W M, Root R K. *Laboratory manual of neutrophil function*. New York: Raven Press, 1986: 74-7.
- 38 Sha'afi R I, White J R, Molski T F P, et al. Phorbol 12-myristate 13-acetate activates rabbit neutrophils without an apparent rise in the level of intracellular free calcium. *Biochem Biophys Res Commun* 1983; **114**: 638-45.
- 39 Di Virgilio F, Lew D P, Pozzan T. Protein kinase C activation of physiological processes in human neutrophils at vanishingly small cytosolic Ca^{2+} levels. *Nature* 1984; **310**: 691-3.
- 40 Smolen J E. Lag period for superoxide anion generation and lysosomal enzyme release from human neutrophils: effects of calcium antagonists and anion channel blockers. *J Lab Clin Med* 1984; **104**: 1-10.
- 41 Lew P D, Wollheim C B, Waldvogel F A, Pozzan T. Modulation of cytosolic-free calcium transients by changes in intracellular calcium-buffering capacity: correlation with exocytosis and O_2 production in human neutrophils. *J Cell Biol* 1984; **99**: 1212-20.
- 42 Ahnfelt-Rønne I, Haagen Nielsen O. The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. *Agents Actions* 1987; **21**: 191-4.
- 43 Borgeat P, Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. *J Biol Chem* 1979; **254**: 2643-6.
- 44 Stenson W F, Parker C W. Metabolism of arachidonic acid in ionophore-stimulated neutrophils. *J Clin Invest* 1979; **64**: 1457-65.
- 45 Palmblad J, Gyllenhammar H, Lindgren J Å, Malmsten C L. Effects of leukotrienes and f-met-leu-phe on oxidative metabolism of neutrophils and eosinophils. *J Immunol* 1984; **132**: 3041-5.
- 46 Curnutte J T. Activation of human neutrophil nicotinamide adenine dinucleotide phosphate, reduced (triphosphopyridine nucleotide, reduced) oxidase by arachidonic acid in a cell-free system. *J Clin Invest* 1985; **75**: 1740-3.
- 47 Sakata A, Ida E, Tominaga M, Onoue K. Arachidonic acid acts as an intracellular activator of NADPH-oxidase in Fc-receptor-mediated superoxide generation in macrophages. *J Immunol* 1987; **138**: 4353-9.
- 48 McPhail L C, Clayton C C, Snyderman R. A potential second messenger role for unsaturated fatty acids: activation of Ca^{2+} dependent protein kinase. *Science* 1984; **224**: 622-4.
- 49 Maridonneau-Parini I, Tringale S M, Tauber A I. Identification of distinct activation pathways of the human neutrophil NADPH-oxidase. *J Immunol* 1986; **137**: 2925-9.
- 50 Walsh C E, Waite B M, Thomas M J, De Chatelet L R. Release and metabolism of arachidonic acid in human neutrophils. *J Biol Chem* 1981; **256**: 7228-34.
- 51 Sircar J C, Schwender C F, Carethers M E. Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. *Biochem Pharmacol* 1983; **32**: 170-2.
- 52 Allgayer H, Eisenburg J, Paumgartner G. Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. *Eur J Clin Pharmacol* 1984; **26**: 449-51.
- 53 Stenson W F, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. *J Clin Invest* 1982; **69**: 494-7.